Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 27.86 0.80% 0.22
ACAD closed up 0.8 percent on Friday, November 17, 2017, on 1.12 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ACAD trend table...

Date Alert Name Type % Chg
Nov 17 New Downtrend Bearish 0.00%
Nov 16 Lower Bollinger Band Walk Other 0.80%
Nov 16 Slingshot Bearish Bearish Swing Setup 0.80%
Nov 16 Calm After Storm Range Contraction 0.80%
Nov 15 Lower Bollinger Band Walk Other 3.80%

Older signals for ACAD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 41.2
52 Week Low 24.31
Average Volume 1,529,642
200-Day Moving Average 32.8758
50-Day Moving Average 35.1058
20-Day Moving Average 32.016
10-Day Moving Average 28.901
Average True Range 1.514
ADX 25.93
+DI 14.19
-DI 34.79
Chandelier Exit (Long, 3 ATRs ) 33.458
Chandelier Exit (Short, 3 ATRs ) 30.552
Upper Bollinger Band 38.8725
Lower Bollinger Band 25.1595
Percent B (%b) 0.2
BandWidth 42.831709
MACD Line -2.3309
MACD Signal Line -1.8097
MACD Histogram -0.5212
Fundamentals Value
Market Cap 3.41 Billion
Num Shares 122 Million
EPS -2.53
Price-to-Earnings (P/E) Ratio -11.01
Price-to-Sales 67.33
Price-to-Book 10.21
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.56
Resistance 3 (R3) 29.39 28.66 29.27
Resistance 2 (R2) 28.66 28.23 28.74 29.18
Resistance 1 (R1) 28.26 27.96 28.46 28.43 29.08
Pivot Point 27.53 27.53 27.63 27.61 27.53
Support 1 (S1) 27.13 27.10 27.33 27.30 26.64
Support 2 (S2) 26.40 26.83 26.48 26.54
Support 3 (S3) 26.00 26.40 26.45
Support 4 (S4) 26.17